2025
The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study
Huelsboemer L, Hosseini H, Klimitz F, Diatta F, Boroumand S, O'Brien C, Parikh N, Stögner V, Formica R, Ko C, Azzi J, Draper E, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study. Journal Of Plastic Reconstructive & Aesthetic Surgery 2025, 103: 286-296. PMID: 40043533, DOI: 10.1016/j.bjps.2025.01.028.Peer-Reviewed Original ResearchDe novo donor-specific antibodiesDonor-specific antibodiesDonor-specific antibody positivityChronic rejectionC4d depositionGraft lossPrognostic relevanceRejection gradeGrades of acute cellular rejectionDonor-specific antibody statusOccurrence of chronic rejectionTime pointsFacial vascularized composite allotransplantationAcute rejection gradeAcute cellular rejectionTissue typing laboratoriesAcute rejection eventsRetrospective cohort studyTransplant-related outcomesFace transplant patientsVascularized composite allotransplantationCellular rejectionTransplant patientsC4d levelsRetrospective analysis
2024
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
Risueño A, See W, Bluemmert I, de Botton S, DiNardo C, Fathi A, Schuh A, Montesinos P, Vyas P, Prebet T, Gandhi A, Hasan M. Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML. Leukemia Research 2024, 140: 107497. PMID: 38564986, DOI: 10.1016/j.leukres.2024.107497.Peer-Reviewed Original ResearchConceptsConventional care regimensMutational burdenR/R AMLCo-mutationsIDH2-R172Co-mutation patternsAssociated with decreased overall survivalRelapsed/refractory acute myeloid leukemiaTargeted next-generation sequencingAML patient cohortNewly diagnosed AMLLow mutational burdenEvent-free survivalLimited treatment optionsAcute myeloid leukemiaGene mutation patternsIDH2 variantsIDH2 R140Prognostic impactOverall survivalPrognostic relevanceSurvival benefitMyeloid leukemiaIDH2 mutationsPatient cohort
2023
Radiomic markers of intracerebral hemorrhage expansion on non-contrast CT: independent validation and comparison with visual markers
Haider S, Qureshi A, Jain A, Tharmaseelan H, Berson E, Zeevi T, Werring D, Gross M, Mak A, Malhotra A, Sansing L, Falcone G, Sheth K, Payabvash S. Radiomic markers of intracerebral hemorrhage expansion on non-contrast CT: independent validation and comparison with visual markers. Frontiers In Neuroscience 2023, 17: 1225342. PMID: 37655013, PMCID: PMC10467422, DOI: 10.3389/fnins.2023.1225342.Peer-Reviewed Original ResearchIndependent validation cohortIntracerebral hemorrhageRadiomic featuresValidation cohortClinical variablesHematoma expansionSpontaneous supratentorial intracerebral hemorrhageNon-contrast head CTSupratentorial intracerebral hemorrhageTomography (CT) of patientsNon-contrast headFuture clinical trialsNon-contrast CTIntracerebral Hemorrhage ExpansionHigh predictive valueBAT scoreHypertensive patientsClinical predictorsPrognostic relevanceFunctional outcomeClinical trialsHead CTHemorrhage expansionClinical trial datasetDiscovery cohortQuality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I
Unger J, Qian L, Redman M, Tavernier S, Minasian L, Sigal E, Papadimitrakopoulou V, Leblanc M, Cleeland C, Dzingle S, Summers T, Chao H, Madhusudhana S, Villaruz L, Crawford J, Gray J, Kelly K, Gandara D, Bazhenova L, Herbst R, Gettinger S, Moinpour C. Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I. Journal Of The National Cancer Institute 2023, 115: 437-446. PMID: 36625510, PMCID: PMC10086628, DOI: 10.1093/jnci/djad003.Peer-Reviewed Original ResearchConceptsQuality of lifeComposite risk modelAppetite lossSeverity scoreWeek 13Advanced squamous cell lung cancerWeek 7Baseline patient-reported outcomesRandomized phase III trialSquamous cell lung cancerPhase III trialsRisk of progressionShortness of breathCell lung cancerPatient-reported outcomesRisk of deathMultivariable linear regressionEffect of treatmentEvaluable patientsPrimary endpointIII trialsOverall survivalMedian ageAdvanced cancerPrognostic relevance
2021
The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma
Sellers CM, Uhlig J, Ludwig JM, Pollak JS, Taddei TH, Stein SM, Lim JK, Kim HS. The effect of chronic viral hepatitis on prognostic value of inflammatory biomarkers in hepatocellular carcinoma. Cancer Medicine 2021, 10: 5395-5404. PMID: 34318618, PMCID: PMC8366096, DOI: 10.1002/cam4.3573.Peer-Reviewed Original ResearchConceptsChronic viral hepatitisViral hepatitisHepatocellular carcinomaMultivariable analysisMedian OSNLR groupHepatitis CKaplan-Meier overall survival curvesCox hazard proportional modelHigher median OSLow baseline NLROverall survival curvesTertiary care institutionBaseline NLRDecreased OSNonviral hepatitisHigh NLRInflammatory biomarkersLow NLRMultivariable adjustmentOverall survivalLymphocyte ratioPrognostic valueRetrospective studyPrognostic relevanceAbsolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values
Kim A, Choi K, Kim M, Kim K, Kang H, Kim S, Chowdhury T, Yu H, Lee C, Lee J, Lee S, Won J, Kim J, Kim Y, Kim T, Park S, Choi S, Shin E, Park C. Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values. Cancer Immunology, Immunotherapy 2021, 70: 1995-2008. PMID: 33416947, PMCID: PMC10991432, DOI: 10.1007/s00262-020-02836-w.Peer-Reviewed Original ResearchConceptsTumor-infiltrating immune cellsHigh-grade gliomasImmune cellsTumor-associated macrophagesImmune microenvironmentRadiomics signatureClinical prognostic relevanceImmune cell numbersImmune cell subpopulationsImmune microenvironment characteristicsTumor immune microenvironmentCore tissueApparent diffusion coefficient (ADC) mapsDiffusion coefficient mapsOverall survivalPrognostic impactPatient groupPrognostic relevanceClinical prognosisImmune characteristicsImmune phenotypeMedian numberM2 TAMsTumor tissueMethodsThe number
2020
Prognostic Models in Myelodysplastic Syndromes
Bewersdorf J, Zeidan A. Prognostic Models in Myelodysplastic Syndromes. 2020, 109-127. DOI: 10.1007/978-3-030-51878-3_7.Peer-Reviewed Original ResearchInternational Prognostic Scoring SystemRisk stratification toolMyelodysplastic syndromeScoring systemStratification toolPrognostic scoring systemClinical trial enrollmentTrial enrollmentPrognostic relevanceDisease characteristicsPatient counselingBody of evidenceTreatment recommendationsPatient subpopulationsIndividual patientsTreatment selectionClinical scenariosPrognostic modelGenetic testingSomatic mutationsSyndromeScoresPatientsPrognostication
2018
The prognostic role of different renal function phenotypes in patients with acute heart failure
Palazzuoli A, Ruocco G, Pellicori P, Incampo E, Di Tommaso C, Favilli R, Evangelista I, Nuti R, Testani JM. The prognostic role of different renal function phenotypes in patients with acute heart failure. International Journal Of Cardiology 2018, 276: 198-203. PMID: 30503187, DOI: 10.1016/j.ijcard.2018.11.108.Peer-Reviewed Original ResearchConceptsAcute heart failureBUN increaseHeart failureIndependent predictorsPrognostic roleAdverse outcomesGlomerular filtration rate reductionBlood nitrogen ureaSigns of HFRenal function deteriorationBUN changeClinical congestionEffective decongestionFunction deteriorationRenal functionSerum creatininePoor outcomePrognostic relevanceComplete resolutionClinical signsPatientsNitrogen ureaHospitalizationBUNOutcomes
2017
Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview
Brivio S, Cadamuro M, Fabris L, Strazzabosco M. Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expression 2017, 18: 31-50. PMID: 29070148, PMCID: PMC5860940, DOI: 10.3727/105221617x15088670121925.Peer-Reviewed Original ResearchConceptsMajority of patientsPrimary liver cancerCancer-related deathPotential prognostic relevanceDevelopment of metastasesPro-oncogenic pathwaysNovel druggable targetsMechanism of actionCholangiocarcinoma invasivenessMesenchymal-like phenotypeDevastating malignancyCurative treatmentMolecular mechanismsPoor prognosisPrognostic relevancePrimary tumorBiliary epitheliumLiver cancerUseful biomarkerAbnormal activationCCA cell invasionMost carcinomasCCA cellsTumor microenvironmentCholangiocarcinomaAPOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism
Chen TW, Lee CC, Liu H, Wu CS, Pickering CR, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP, Chang YS. APOBEC3A is an oral cancer prognostic biomarker in Taiwanese carriers of an APOBEC deletion polymorphism. Nature Communications 2017, 8: 465. PMID: 28878238, PMCID: PMC5587710, DOI: 10.1038/s41467-017-00493-9.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaSquamous cell carcinomaCell carcinomaTaiwanese oral squamous cell carcinomasClinical prognostic relevanceBetter overall survivalCancer prognostic biomarkersExpression of APOBEC3AOverall survivalPrognostic relevanceTaiwanese patientsPrognostic biomarkerSecond cohortGermline polymorphismsCancer typesProminent cancerMutational profileDeletion polymorphismPatientsCarcinomaMutation signaturesExpressionPolymorphismCohortTumorsQuantitative Assessment of Coronary Microvascular Function
Feher A, Sinusas AJ. Quantitative Assessment of Coronary Microvascular Function. Circulation Cardiovascular Imaging 2017, 10: e006427. PMID: 28794138, PMCID: PMC5678979, DOI: 10.1161/circimaging.117.006427.Peer-Reviewed Original ResearchMeSH KeywordsComputed Tomography AngiographyCoronary AngiographyCoronary CirculationEchocardiographyHeart DiseasesHumansMagnetic Resonance ImagingMicrocirculationMyocardial Perfusion ImagingPositron-Emission TomographyPredictive Value of TestsPrognosisReproducibility of ResultsTomography, Emission-Computed, Single-PhotonConceptsCoronary microvascular dysfunctionMyocardial blood flowMicrovascular dysfunctionBlood flowMyocardial perfusionCoronary microvascular impairmentCoronary microvascular functionEpicardial coronary arteriesNormal myocardial perfusionMyocardial contrast echocardiographyAbsolute myocardial blood flowImportant prognostic relevanceMagnetic resonance imagingPositron emission tomographySingle photon emissionMicrovascular impairmentMicrovascular functionMultiple imaging modalitiesPrognostic relevanceCoronary arteryCoronary flowCoronary perfusionContrast echocardiographyClinical valueFunctional microcirculation(1292) Prognostic Relevance of INTERMACS Defined Right Heart Failure After Left Ventricular Assists Device Implantation
Muslem R, Ong C, Gilotra N, Sharma K, Houston B, Zehr K, Duquaine D, Whitman G, Caliskan K, Russell S, Tedford R. (1292) Prognostic Relevance of INTERMACS Defined Right Heart Failure After Left Ventricular Assists Device Implantation. The Journal Of Heart And Lung Transplantation 2017, 36: s420-s421. DOI: 10.1016/j.healun.2017.01.1204.Peer-Reviewed Original Research
2016
Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications
Lee L, Yantiss R, Sadot E, Ren B, Calvacanti M, Hechtman J, Ivelja S, Huynh B, Xue Y, Shitilbans T, Guend H, Stadler Z, Weiser M, Vakiani E, Gönen M, Klimstra D, Shia J. Diagnosing colorectal medullary carcinoma: interobserver variability and clinicopathological implications. Human Pathology 2016, 62: 74-82. PMID: 28034727, PMCID: PMC5392420, DOI: 10.1016/j.humpath.2016.12.013.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBiopsyCarcinoma, MedullaryCell DifferentiationColorectal NeoplasmsDNA Mismatch RepairDNA Repair EnzymesFemaleHumansImmunohistochemistryMaleMiddle AgedObserver VariationPredictive Value of TestsPrognosisReproducibility of ResultsTerminology as TopicYoung AdultConceptsMedullary carcinomaDiagnosis of medullary carcinomaGroup 3World Health Organization criteriaDiagnose medullary carcinomaSpectrum of histologyHistological subtypesMedullary tumorsMismatch repair deficiencyPrognostic relevanceMismatch repair protein deficiencyOrganization criteriaImproved survivalImprove prognosisClinicopathological implicationsGastrointestinal pathologistsInterobserver agreementMorphologic spectrumColorectal adenocarcinomaInterobserver variabilityGroup 1CarcinomaMolecular pathogenesisWorld Health OrganizationProtein deficiency
2013
Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas
Viray H, Bradley WR, Schalper KA, Rimm DL, Rothberg BE. Marginal and Joint Distributions of S100, HMB-45, and Melan-A Across a Large Series of Cutaneous Melanomas. Archives Of Pathology & Laboratory Medicine 2013, 137: 1063-73. PMID: 23899062, PMCID: PMC3963468, DOI: 10.5858/arpa.2012-0284-oa.Peer-Reviewed Original ResearchConceptsHMB-45Primary tumorCutaneous melanomaLarge seriesMelanoma-specific survivalMelanoma primary tumorsGroup of antigensLarge tissue microarrayClinicopathologic covariatesClinicopathologic criteriaPrognostic relevanceHistopathologic profileClinicopathologic correlatesAntigen expressionClinicopathologic parametersMelanoma markersTissue microarrayPositive expressionSurvival analysisMelanomaMelanS100Melanoma cellsBivariate associationsSignificant differencesUSP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer
Bayraktar S, Barrera A, Liu D, Pusztai L, Litton J, Valero V, Hunt K, Hortobagyi GN, Wu Y, Symmans F, Arun B. USP-11 as a Predictive and Prognostic Factor Following Neoadjuvant Therapy in Women With Breast Cancer. The Cancer Journal 2013, 19: 10-17. PMID: 23337751, PMCID: PMC3568679, DOI: 10.1097/ppo.0b013e3182801b3a.Peer-Reviewed Original ResearchConceptsNeoadjuvant systemic therapyPathological complete responseBreast cancerKaplan-Meier product-limit methodBetter survival outcomesDisease-free survivalOverall survival rateRisk of recurrenceProduct-limit methodLogistic regression modelsNeoadjuvant therapyComplete responsePrognostic factorsSystemic therapyDisease recurrencePrognostic relevanceSurvival outcomesHigh riskPatientsSurvival rateTumorsCancerRecurrencePolymerase inhibitionUbiquitin-specific protease family
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply